Table 1.
Subject characteristics. All subjects with chemotherapy had vincristine and carboplatin, except for subject 14 who received sunitinib malate as part of a trial for plexiform neurofibromas
| Subject | Age at MRI (years) | NF1 | Optic pathway tumor | Visual symptoms | Chemotherapy |
|---|---|---|---|---|---|
| 1 | 9 | Y | Y | Y-Left eye decreased vision | Y |
| 2 | 7 | Y | Y | N | N |
| 3 | 13 | Y | Y | N | N |
| 4 | 14 | Y | Y | Y-right vision loss | Y |
| 5 | 3 | Y | Y | Y-nystagmus and worsening vision | Y |
| 6 | 7 | Y | Y | N | N |
| 7 | 3 | Y | N | N | N |
| 8 | 15 | Y | Y | Y-Left eye decreased vision | Y |
| 9 | 18 | Y | Y | N | N |
| 10 | 7 | Y | Y | N | N |
| 11 | 6 | Y | N | N | N |
| 12 | 11 | Y | Y | Y-left eye decreased vision | Y |
| 13 | 12 | Y | Y | Y-decreased vision, nystagmus | Y |
| 14 | 12 | Y | N | N | Y |
| 15 | 13 | Y | N | N | N |
| 16 | 12 | Y | N | N | N |
| 17 | 8 | Y | N | N | N |
| 18 | 7 | Y | Y | N | N |
| 19 | 2 | Y | N | N | N |
| HC | 5 | N | N | N | N |
| HC | 5 | N | N | N | N |
| HC | 4 | N | N | N | N |
| HC | 3 | N | N | N | N |
| HC | 17 | N | N | N | N |